The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Department of Obstetrics and Gynaecology and Paediatrics, Monash University, Clayton, VIC, Australia.
Front Endocrinol (Lausanne). 2020 Mar 3;11:86. doi: 10.3389/fendo.2020.00086. eCollection 2020.
Fetal growth restriction (FGR) and prematurity are often co-morbidities, and both are risk factors for lung disease. Despite advances in early delivery combined with supportive ventilation, rates of ventilation-induced lung injury (VILI) remain high. There are currently no protective treatments or interventions available that target lung morbidities associated with FGR preterm infants. Stem cell therapy, such as umbilical cord blood (UCB) cell administration, demonstrates an ability to attenuate inflammation and injury associated with VILI in preterm appropriately grown animals. However, no studies have looked at the effects of stem cell therapy in growth restricted newborns. We aimed to determine if UCB treatment could attenuate acute inflammation in the first 24 h of ventilation, comparing effects in lambs born preterm following FGR with those born preterm but appropriately grown (AG). Placental insufficiency (FGR) was induced by single umbilical artery ligation in twin-bearing ewes at 88 days gestation, with twins used as control (appropriately grown, AG). Lambs were delivered preterm at ~126 days gestation (term is 150 days) and randomized to either immediate euthanasia (unventilated controls, AG and FGR) or commenced on 24 h of gentle supportive ventilation (AG and FGR) with additional cohorts receiving UCB treatment at 1 h (AG, FGR). Lungs were collected at post-mortem for histological and biochemical examination. Ventilation caused lung injury in AG lambs, as indicated by decreased septal crests and elastin density, as well as increased inflammation. Lung injury in AG lambs was attenuated with UCB therapy. Ventilated FGR lambs also sustained lung injury, albeit with different indices compared to AG lambs; in FGR, ventilation reduced septal crest density, reduced alpha smooth muscle actin density and reduced cell proliferation. UCB treatment in ventilated FGR lambs further decreased septal crest density and increased collagen deposition, however, it increased angiogenesis as evidenced by increased vascular endothelial growth factor (VEGF) expression and vessel density. This is the first time that a cell therapy has been investigated in the lungs of growth restricted animals. We show that the uterine environment can alter the response to both secondary stress (ventilation) and therapy (UCB). This study highlights the need for further research on the potential impact of novel therapies on a growth restricted offspring.
胎儿生长受限(FGR)和早产通常是并存的,并且都是肺部疾病的风险因素。尽管早期分娩结合支持性通气技术有所进步,但通气引起的肺损伤(VILI)的发生率仍然很高。目前尚无针对与 FGR 早产儿相关的肺部疾病的保护性治疗或干预措施。脐带血(UCB)细胞给药等干细胞治疗能够减轻适当生长的早产儿动物与 VILI 相关的炎症和损伤。然而,尚无研究观察干细胞治疗对生长受限新生儿的影响。我们旨在确定 UCB 治疗是否可以减轻通气后 24 小时内的急性炎症,比较 FGR 出生的早产羔羊与适当生长(AG)的早产羔羊的效果。在妊娠 88 天时,通过单脐动脉结扎在双胎妊娠母羊中诱导胎盘功能不全(FGR),并将双胞胎作为对照(适当生长,AG)。羔羊在妊娠 126 天左右早产(足月为 150 天),并随机分为立即安乐死(未通气对照,AG 和 FGR)或开始接受 24 小时温和支持性通气(AG 和 FGR),并在 1 小时时接受 UCB 治疗(AG,FGR)。在死后收集肺组织进行组织学和生化检查。通气导致 AG 羔羊的肺损伤,表现为隔嵴减少和弹性蛋白密度降低,以及炎症增加。UCB 治疗减轻了 AG 羔羊的肺损伤。通气的 FGR 羔羊也发生了肺损伤,但其与 AG 羔羊的指标不同;在 FGR 中,通气降低了隔嵴密度,降低了α平滑肌肌动蛋白密度并降低了细胞增殖。通气的 FGR 羔羊的 UCB 治疗进一步降低了隔嵴密度并增加了胶原蛋白沉积,但增加了血管生成,表现为血管内皮生长因子(VEGF)表达和血管密度增加。这是首次在生长受限动物的肺部研究细胞治疗。我们表明,子宫环境可以改变对二次应激(通气)和治疗(UCB)的反应。这项研究强调了需要进一步研究新型疗法对生长受限后代的潜在影响。